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Background: Off-label and unlicensed (OLUL) prescribing has been prevalent in pediatric practice. Using data from
a prospective cohort study of adverse drug reactions (ADRs) among pediatric inpatients, we aimed to test the
hypothesis that OLUL status is a risk factor for ADRs.
Methods: A nested case–control study was conducted within a prospective cohort study. Details of all medicines
administered were recorded, including information about OLUL status. The odds ratio for OLUL medicines being
implicated in a probable or definite ADR was calculated. A multivariate Cox proportional hazards regression model
was fitted to the data to assess the influence that OLUL medicine use had on the hazard of an ADR occurring.
Results: A total of 10,699 medicine courses were administered to 1,388 patients. The odds ratio (OR) of an OLUL
medicine being implicated in an ADR compared with an authorized medicine was 2.25 (95% confidence interval
(CI) 1.95 to 2.59). Medicines licensed in children but given to a child below the minimum age or weight had the
greatest odds of being implicated in an ADR (19% of courses in this category were implicated, OR 3.54 (95% CI 2.82
to 4.44). Each additional OLUL medicine given significantly increased the hazard of an ADR (hazard ratio (HR) 1.3
95% CI 1.2 to 1.3, P <0.001). Each additional authorized medicine given also significantly increased the hazard
(HR 1.2 95% CI 1.2 to 1.3, P <0.001).
Conclusions: OLUL medicines are more likely to be implicated in an ADR than authorized medicines. The number
of medicines administered is a risk factor for ADRs highlighting the need to use the lowest number of medicines, at
the lowest dose for the shortest period, with continual vigilance by prescribers, in order to reduce the risk of ADRs.
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The licensing of a new drug by regulatory authorities such
as the European Medicines Agency is based on the quality,
safety and efficacy of the medicine. If the manufacturer
satisfies these criteria, the drug will be granted a marketing
authorization (MA). The MA sets out terms of use for the
medicine. However, this does not preclude the use of* Correspondence: jennifer.bellis@alderhey.nhs.uk
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2013the medicine outside of those terms which is known as
off-label prescribing. Additionally, clinicians can also
prescribe unlicensed medicines, that is, where the drug
does not have a MA in their country. In some cases
there is a logical basis to the prescription of the drug
off-label. In pediatric practice, off-label and unlicensed
(OLUL) prescribing has been prevalent because of the
lack of assessment of the use of drugs in children during
the drug development process [1]. The reported incidence
of OLUL use of medicines in children ranges from 36% to
100% [2]. Although the recently introduced pediatricd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Equity Act of 2003 in the US [4] are likely to improve the
situation, it is going to take time.
The use of OLUL medicines in children is a potential
risk factor for adverse drug reactions (ADRs). For instance,
in a study of 936 patients, Turner et al. found that the
proportion of OLUL medicines administered to pediatric
inpatients was significantly associated with ADR risk [5].
However, this has not been demonstrated by all studies,
many of which were small, employed different methodolo-
gies and used inexact and varying definitions. Thus, there
is a need for further research in this area [6].
Using the dataset generated by our study evaluating the
incidence of ADRs in pediatric inpatients (see accompany-
ing paper), we have employed a nested case–control design
to assess the impact of OLUL prescribing on ADR risk
in pediatric inpatients. We hypothesized that OLUL pre-
scribing was a risk factor for ADRs in pediatric inpatients.
Methods
Selection of cases and controls
We have utilized a prospective cohort study design,
undertaken between 1 October 2009 and 30 September
2010, to determine the burden of ADRs in pediatric inpa-
tients (see accompanying paper). The prospective cohort
included all inpatients 0 to 16 years old, with the exception
of patients in the operating theater, recovery or in the
department of radiology, or in the pediatric intensive
care unit (PICU) for the entire duration of their admission.
Since some patients had multiple admissions over the
study period, the cases for the nested case–control study
were children on their first admission who had experienced
at least one probable or definite ADR (n = 694). These
cases were matched 1:1 to controls who were children on
their first admission who had not experienced any probable
or definite ADRs. Matching was based on the closest
date and time of admission, which were chosen in order
to ensure that we could assess the relevance of factors
such as age and gender as predictors for the occurrence of
ADRs. A nested case-control design was chosen because it
was not possible to follow up all patients across all their
admissions (n = 6,601) in the prospective cohort study
and the design allowed us to assess carefully the drugs
prescribed and whether those drugs were prescribed
within the MA, in both cases and controls.
Data collection
Detailed information about each patient was recorded
as described in the accompanying paper. This included
the name, route, dose and frequency of all medicines
administered and the indication where this was thought to
need clarification. A medicine course was defined as the
administration of one type of medicine at least once during
the admission; this encompassed regular medicines (forexample, daily anti-epileptic treatment), short courses
(for example, antibiotics) and intermittent doses (for
example, paracetamol given as required). Suspected ADRs
to medicines administered were recorded and assessed in
detail and causality assessment was undertaken using the
Liverpool Causality Assessment Tool (LCAT) [7]. If an
ADR was found to be probable or definite, the suspected
medicine course(s) were then referred to as ‘implicated’ in
an ADR. For each of the 1,388 patients, their record of
medicines administered was updated to include a detailed
off-label or unlicensed category for each medicine on each
day it was administered. The category was assigned by
one researcher (JRB) who discussed these classifications
with an experienced pediatric clinical pharmacist (AJN).
The prospective cohort study did not record theater
medicines unless they were implicated in a suspected
ADR; these medicines were, therefore, excluded from
the case–control study. There were 30 possible off-label
categories and five unlicensed medicine categories (Table 1).
Categories for off-label use were allocated for each medi-
cine according to the reason(s) why their use was deemed
off-label when compared to the terms of the MA for that
medicine. The terms of the MA were found in the
Summary of Product Characteristics (SmPC) available
online from the Electronic Medicines Compendium [8].
With regard to age, if the SmPC mentioned children, the
definition of this was assumed to be 28 days to 18 years
(as per the definition in the pediatric regulation [3]). If no
specific information pertaining to use in neonates was
provided, the use of that medicine in neonates was consid-
ered to be off-label. Although it was certainly not the case,
it was assumed that all neonates were born at term because
gestational age was not recorded in this study. Due to the
complex nature of the regimes used to treat malignant
disease, the classification of cytotoxic medicines was
simplified by consulting the British National Formulary
for Children (BNFC) for cytotoxic medicines with a UK
MA [9]. If the BNFC monograph stated the relevant indi-
cation, it was assumed that the use was authorized. If the
BNFC monograph stated ‘not licensed in children’ the use
was considered to be off-label. The implications of dosage
form manipulation by parents or nursing staff, such as the
crushing of tablets or the addition of licensed medicines to
food or drinks for ease of administration, was considered
to be outside the scope of our analysis.Statistical methods
Odds ratios (OR) with 95% confidence intervals (95% CI)
were calculated for all OLUL medicines implicated in a
probable or definite ADR. Additionally, ORs with accom-
panying 95% CI were calculated for each OLUL category
implicated in a probable or definite ADR in comparison to
authorized medicines.
Table 1 Off-label and unlicensed categories
Category Definition
Off-label medicines Medicines licensed for use
in children
1 Authorized - medicine used within the terms of its marketing authorization
2 Contraindication exists
3 Dose greater than recommended
4 Dose greater than recommended and contraindication exists
5 Not licensed in child of this age (or child below minimum weight stated)
6 Not licensed in child of this age and contraindication exists
7 Not licensed by this route
8 Not licensed by this route and contraindication exists
9 Not licensed by this route or in a child of this age
10 Not licensed by this route or in a child of this age and contraindication exists
11 Not licensed for this indication
12 Not licensed for this indication and contraindication exists
13 Not licensed for this indication or at this dose
14 Not licensed for this indication or at this dose and contraindication exists
15 Not licensed for this indication or at this age
16 Not licensed for this indication or at this age and a contraindication exists
17 Not licensed for this indication or by this route
18 Not licensed for this indication or by this route and a contraindication exists
19 Not licensed for this indication or by this route or at this age
20 Not licensed for this indication or by this route or at this age and a
contraindication exists
Medicines not licensed for use
in children
21 Not licensed for use in children
22 Not licensed for use in children and a contraindication exists
23 Not licensed for use in children or in adults by this route
24 Not licensed for use in children or in adults by this route and a
contraindication exists
25 Not licensed for use in children or in adults for this indication
26 Not licensed for use in children or in adults for this indication and a
contraindication exists
27 Not licensed for use in children or in adults for this indication or in adults
by this route
28 Not licensed for use in children or in adults for this indication or in adults
by this route and a contraindication exists.
Medicines excluded from analysis 29 Category cannot be assigned
30 Theater medicine
Unlicensed medicines 31 Prepared extemporaneously
32 Manufactured under a specials manufacturing license
33 Chemical
34 Import
35 Awaiting a MA (for example, previous trial medicine)
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ADR was fit to the data. Results are given in terms of the
hazards ratio (HR) and associated 95% CI. In addition to
the number of OLUL medicines, the following risk factors
were included in the model: age, gender, having received
a general anesthetic (GA), oncology patient status and
the number of authorized medicines. Due to clinical im-
portance, all risk factors remained in the final model.All statistical analysis was carried out using the statistical
software package R (version 2.13.2) using a two-sided
significance level of 0.05 (5%) throughout.
Reporting
This study was reported according to the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines [10].
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This study used routinely collected clinical data in an
anonymized format. The Chair of Liverpool Paediatric
LREC informed us that this study did not require individual
patient consent or review by an Ethics Committee.
Results
Participants
Clinical data for 1,388 patients were analyzed throughout
their first admission. A total of 694 (50%) were cases; 634
(45.6%) were female; 294 (21.2%) were <1 year old, 341
(24.6%) were 1 to 4 years old, 384 (27.7%) were 5 to 11
years old and 369 (26.6%) were teenagers (>12 years old).
The median age was 5.9 years (interquartile range (IQR)
1.4 to 12.4 years). A total of 10,699 drug courses were
administered in this study.
Medicine courses
A total of 10,699 medicine courses were administered to
the 1,388 patients included in this study. Within this nested
cohort, there were 785 suspected ADRs deemed definite or
probable in 694 patients during their first admission. Of the
suspected ADRs, 62 (7.9%) were deemed definite and 723
(95.1%) probable. Of these ADRs, 505 (64.3%) involved one
medicine course, 172 (21.9%) involved two medicine
courses, 77 (9.8%) involved three and 31 (3.9%) involved
four or more. Of the 10,699 total medicine courses, 10,145
(94.8%) could be categorized using one of the definitions
listed in Table 1. The remaining 554 (5.2%) courses could
not be categorized because the prescription record did not
provide the required information (for example, missing
dose information or insufficient detail about the exact
preparation used).
A total of 6,980 (68.8%) of all medicine courses were
authorized, 2,407 (23.7%) were off-label and 758 (7.5%)
were unlicensed. A total of 435 (6.2%) of all authorized
medicine courses were implicated in at least one probable
or definite ADR compared with 298 (12.4%) of off-label
medicine courses and 113 (14.9%) of unlicensed medicine
courses. Comparing the rate of OLUL prescribing among
age groups, the neonatal category had the fewest patients
(n = 75) but the greatest proportion of OLUL prescrip-
tions (58.9%). The proportion of OLUL prescriptions
implicated in at least one ADR was greatest in the
‘school-aged’ category (17.0% of prescriptions; see Additional
file 1). The OR ratio of an OLUL medicine being implicated
in an ADR when compared with an authorized medicine
course was 2.25 (95% CI 1.95 to 2.59).
In total, 19 of the OLUL categories were utilized. Table 2
shows the number of medicine courses in each of these
OLUL categories. Category 11: drug licensed for children
but given for a different indication is the most common
category of off-label medicine use (n = 764; 31.7%).
Categories 3, 5 and 11 together represented 2,050 (85.2%)of all off-label medicine courses. Category 32: manufactured
under a specials license was the most common category of
unlicensed medicine (n = 577; 76%).
Table 2 shows the proportion of medicine courses from
each category implicated in at least one probable or definite
ADR in comparison to the proportion of authorized medi-
cine courses implicated (n = 6,980; 6.2%). Further analysis
was completed on categories that contained >100 medi-
cine courses. Results showed that category 3: medicines
licensed for use in children but given at a dose greater
than recommended had a lower risk of being implicated
in an ADR than category 1: authorized medicines (OR
0.42, 95% CI 0.26 to 0.67). Category 5: medicines licensed
in children but given to a child below the minimum age
or weight had the greatest risk of being implicated in an
ADR (OR 3.54, 95% CI 2.82 to 4.44).
Table 3 shows the proportion of drug courses impli-
cated in a probable or definite ADR specifically for drugs
with more than 100 courses administered – together with
the proportion of courses that were categorized as OLUL.
Fentanyl via the epidural route had 44.3% of courses
implicated with 100% of courses categorized as unlicensed.
Fentanyl via other routes had 48.0% of courses implicated
in at least one ADR with 99.3% of courses categorized as
off-label. Morphine via any route had 35% of courses
implicated, of which 50.9% were OLUL. Table 4 shows
the four most frequently implicated medicines by OLUL
category. The majority of fentanyl courses were category
11: given for a different indication and 88.0% of impli-
cated fentanyl courses fell into this category. These
courses were mainly fentanyl administered in nurse- or
patient-controlled analgesia pumps for post-operative
pain management. Just under two thirds of morphine
courses were authorized and 49.1% of implicated morphine
courses fell into this category whereas just over a third of
morphine courses were category 5: not licensed in a child
of this age or a child below the minimum weight stated
and 50.3% of implicated morphine courses fell into this
category. Since the OLUL use of morphine and fentanyl
was common and ADRs to these medicines were also
common, we examined the impact of removing these
medicines, regardless of category, from our analysis. This
left 6,667 authorized courses and 2,712 OLUL courses that
were administered; this resulted in at least one ADR associ-
ated with 349 authorized and 248 OLUL courses. However,
despite this, OLUL medicines were still more likely to be
implicated in an ADR than authorized medicines (OR
1.82, 95% CI 1.54 to 2.16).
ADR risk factors
Multivariate risk factor analysis of the nested cohort
(Table 5) showed that age on admission and receipt of a
GA both had a significant effect on ADR risk. Gender
and oncology patient status did not have a significant
Table 2 Total number of medicine courses in each authorized, off-label or unlicensed category and number implicated
in at least one PD ADR (n = 10,145)
Categorya Number of
medicine courses
% of courses implicated
in at least one PD ADR
Odds ratio of ADR
versus authorized
95% CI
Off-label medicines Medicines licensed for
use in children
1 6,980 6.2 1.00 -
2 1 0 - -
3 698 2.7 0.42 0.26 to 0.67
5 588 19.0 3.54 2.82 to 4.44
6 1 0 - -
7 61 9.8 1.64 0.70 to 3.83
11 764 14.3 2.50 2.00 to 3.13
13 8 0 - -
15 35 25.7 5.21 2.43 to 11.18
17 21 0 - -
19 2 0 - -
Medicines not licensed
for use in children
21 215 18.6 3.44 2.41 to 4.91
22 1 100.0 - -
23 1 0 - -
25 11 18.2 3.34 0.72 to 15.52
Unlicensed medicines 31 143 14.7 2.59 1.61 to 4.16
32 577 14.9 2.64 2.05 to 3.38
33 1 0 - -
34 37 16.2 2.91 1.21 to 7.02
asee Table 1 for category definitions. PD ADR, probable or definite ADR; adverse drug reaction; CI, confidence interval.
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increased by 30% with each additional OLUL drug given
(median daily number of OLUL drugs administered 1;
IQR 0 to 2). Similarly, the hazard of an ADR increased
by 20% with each additional authorized drug (median
daily number of authorized drugs administered 2; IQR 1
to 3).
Discussion
In the largest study undertaken so far, we have investi-
gated the role of OLUL medicines in predisposing
pediatric inpatients to ADRs. The prevalence of OLUL
prescriptions in pediatric inpatients ranges from 18% to
60% and 3.4% to 36%, respectively [2]. The corresponding
figures in our dataset were 23.7% and 7.5%, respectively.
These are collectively similar to previous UK studies,
where combined OLUL prescribing rates of 35% [5] and
30% [11] have been reported. This is perhaps not surprising
since many of the medicines used in children are the
older generic medicines, which pre-date the introduction
of pediatric regulation in 2007 [3]. Our findings, however,
contrast with OLUL prescribing rates in other European
countries, where rates of up to 66% have been reported
[11]. This reflects differences in study settings, definitions
of OLUL prescribing and pharmacy practice between
countries. With respect to the latter, for example, there is
extensive modification and manufacture of medicines byhospital pharmacies in the Netherlands [12]. Our data
show that OLUL medicines were significantly more likely
to be implicated in an ADR than medicines used within
the terms of their MA (OR 2.25, 95% CI 1.95 to 2.59). The
risk estimate is higher than that found previously [5,13]
which may be a reflection of the fact that the previous
studies were smaller (OR 1.5, 95% CI 1.11 to 1.93 and OR
1.08, 95% CI 0.50 to 2.35) [5,13], looked at different ward
types (for example, included pediatric intensive care) [5]
and used different definitions of OLUL medicines [13].
We also categorized ADR risk according to the type of
OLUL medicine use. By focusing on six categories which
all had more than 100 medicine courses, we found that (1)
medicines licensed for use in children but given at a dose
greater than recommended had a lower risk of being
implicated in an ADR than authorized medicines; and (2)
medicines licensed in children but given to a child below
the minimum age or weight had the greatest risk of being
implicated in an ADR. These two findings seem counter-
intuitive but can be explained by the fact that 69% of the
medicine courses given at a higher dose than recom-
mended were paracetamol. This reflects the widespread
use of 15 to 20 mg/kg doses for ‘severe symptoms’ as
recommended in the BNFC [9]. Paracetamol at these
doses is relatively safe, particularly in in-patient settings
and, indeed, paracetamol was rarely implicated in ADRs
throughout the entire study (Table 4).
Table 3 Medicines course frequency administered, implicated and off-label, unlicensed or unknown (only medicines
with > 100 courses shown, n = 7,007)
Medicine
(number of courses)
Number of courses
off-label or
unlicensed (%)a
Number of authorized
courses implicated in at
least one PD ADR (%)
Number of off-label or
unlicensed courses implicated
in at least one PD ADR (%)
Number of
courses
unknown
Medicines with only authorized
courses
Cefuroxime (245) 0 (0%) 15 (6.5%) - 1
Cefotaxime (388) 0 (0%) 40 (10.3%) - 0
Medicines with off-label
courses
Chlorphenamine (339) 1 (0.3%) 1 (0.3%) 0 1
Diazepam (107) 1 (1.9%) 1 (1.0%) 0 0
Ibuprofen (545) 26 (4.8%) 4 (0.8%) 1 (3.8%) 0
Lactulose (272) 13 (4.8%) 7 (2.7%) 1 (0.1%) 0
Cefalexin (148) 9 (6.1%) 8 (5.8%) 1 (11.0%) 0
Metronidazole (257) 21 (8.2%) 19 (8.0%) 3 (14.3%) 0
Furosemide (110) 13 (11.8%) 13 (13.4%) 2 (15.4%) 0
Paracetamol (1786) 596 (33.4%) 1 (0.1%) 0 (0%) 2
Ondansetron (550) 290 (52.7%) 18 (8.5%) 14 (2.5%) 48
Salbutamol (146) 84 (57.5%) 3(4.8%) 10 (11.9%) 0
Ranitidine (109) 65 (59.6%) 1 (2.3%) 0 (0%) 0
Dexamethasone (166) 107 (64.5%) 7(13.5%) 3 (2.8%) 7
Fentanyl (150) 149 (99.3%) 0 (0%) 72 (48%) 0
Medicines with unlicensed
courses
Fentanyl and
Levobupivicaine
epidural (106)
106 (100.0%) - 47 (44.3%) 0
Medicines with off-label
and unlicensed courses
Codeine Phosphate (752) 12 (1.6%) 49 (10.1%) 0 (0%) 257
Morphine (500) 198 (39.8%) 86 (28.5%) 89 (44.9%) 0
Diclofenac (331) 149 (45.0%) 2 (8.7%) 3 (2.0%) 159
aDrugs within each category listed in ascending order of % off-label or unlicensed. PD ADR, probable or definite adverse drug reaction.
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ADRs were the administration of a GA and the number
of medicines administered per day, consistent with the
findings of the cohort study (see accompanying paper).
Furthermore, our finding is consistent with that of
Santos et al. [14] who found that off-label medicine
use was significantly associated with ADR risk (RR
2.44, 95% CI 2.12 to 2.89). However, in our study, we
have dissected medicine use and show that the number
of OLUL medicines administered per day had anTable 4 Off-label and unlicensed category proportions for me
PD ADR
Categorya Fentanyl
(implicated)
Fentanyl + Levo
Epidural (imp
1 1 (0) -
3 - -
5 1 (0) -
11 136 (66) -
15 12 (6) -
29 - -
32 - 106 (47
Total 150 (72) 106 (47
asee Table 1 for category definitions. PD ADR, probable or definite adverse drug reainfluence on ADR risk similar to that of the number of
authorized medicines administered per day. Most studies,
including those in adults, have shown that ADR risk
increases with the number of medicines used by pa-
tients, [5,13,15-17] which reflects the complex inter-
action that occurs between drugs targeting different
biological systems within the body, the interaction with
disease (that is, sicker patients are more likely to require
a higher number of medicines) and the occurrence of
drug-drug interactions.dicines with >10% of courses implicated in at least one
bupivicaine
licated)
Morphine
(implicated)
Codeine
(implicated)
302 (86) 483 (49)
2 (0) -
189 (88) 9 (0)
6 (1) -
- -
- 257 (33)
) 1 (0) 3 (0)
) 500 (175) 752 (99)
ction.
Table 5 ADR risk factors assessed by multivariate analysis
Covariate HR (95% CI) P-value
Gender Female 1 0.152
Male 0.896 (0.770 to 1.042)
Age on admission (years) 1.036 (1.021 to 1.052) <0.001
Received a GA No 1 <0.001
Yes 5.295 (4.417 to 6.349)
Oncology No 1 0.655
Yes 0.926 (0.661 to 1.298)
Number of authorized medicines 1.217 (1.171 to 1.263) <0.001
Number of off-label and/or unlicensed medicines 1.267 ( 1.201 to 1.336) <0.001
Number of uncategorized medicines 1.138 (0.969 to 1.338) 0.116
ADR, adverse drug reaction; CI, confidence interval; GA, general anesthesia; HR, hazard ratio.
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rized medicines, highlight the need for good prescribing
practice in reducing ADRs. Thus, the minimum number
of drugs should be given for the treatment of a disease
process, at the lowest possible dose for the shortest
possible time. Nevertheless, our data implicate OLUL
medicines as risk factors for ADRs in pediatric inpatients.
Off-label use is complicated and in some cases can be
justified by the fact that evidence which may not necessarily
have led to a change in the SmPC is available in the
scientific literature as a result of academic investigations
[18]. For instance, a substantial proportion of off-label pre-
scribing in pediatric oncology may reflect evidence-based
protocol recommendations for specific oncological diseases.
In contrast, the evidence for the use of some analgesic med-
icines in children is less robust [1]. Some of the most com-
monly implicated medicines in our study were frequently
used off-label (for example, dexamethasone). However, we
have no evidence that if these products were used in ac-
cordance with a MA, they would be implicated in any fewer
ADRs. An area of concern identified in our data is the use
of fentanyl, either when used off-label or unlicensed, where
about 48% of courses were implicated in ADRs. A key issue
with fentanyl may be the dose used in children, suggesting
a need for further evaluation of dosing strategies.
With all drugs, irrespective of their licensing status, the
dose administered and, thus, the systemic exposure to that
medicine is an important determinant of the likelihood of
an ADR. The importance of this is highlighted by our
finding that medicines licensed in children but given to a
child below the minimum age or weight had the greatest
risk of being implicated in an ADR, reflecting the lack of
pharmacokinetic data in children of different ages and/or
weights. Advances in the development, and application, of
pediatric pharmacokinetic models will be important in
defining, and implementation of, age- and weight (or
body surface area)- specific dosing regimens [19]. While
such approaches are now being incorporated in pediatricinvestigation plans for new medicines, the challenge for all
stakeholders will be how to improve this knowledge for
medicines already on the market, most of which are not
only generic off-patent compounds but are also the most
widely used.
Our study has several limitations: we required a mini-
mum amount of information to be available about the use
of a medicine before it could be categorized as off-label.
The absence of this information was a result of how medi-
cines were recorded on prescription charts; in general, they
were prescribed by the name of the active ingredient and
details such as the exact preparation administered were
not recorded. Hence, the prescription chart records were
adequate for their primary purpose but not for our study.
We did not consider the implications of dosage form
manipulation by parents or nursing staff, but this is a
significant aspect of drug administration in pediatrics
which does warrant investigation [20]. Further limitations
are the assumptions outlined in our methodology which
pertain to the SmPC definitions of age, gestational age and
the classification of cytotoxic medicines.
Conclusion
In one of the largest inpatient pediatric studies, we have
shown that OLUL prescribing is a risk factor for ADRs
and identified some drugs/classes where further work is
needed. The reasons for this are complex and varied, and
the finding must be put in context of the fact that the
number of medicines per se, irrespective of the licensing
status, is also a risk factor for ADRs. Better dosing
schedules for medicines, particularly those with a narrow
therapeutic index, are likely to be key in reducing the
burden of ADRs in children. Clinicians prescribing for
children should be vigilant for the occurrence of ADRs
and should prescribe the minimum number of drugs at
the lowest possible dose and shortest duration of time,
with continual monitoring to stop drugs when relevant
and to ensure that ADRs are detected as early as possible.
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: Distribution of authorized, OLUL medicine
courses (n = 10,145) by patient age category. Count of OLUL
medicine courses by age category, count of authorized medicine courses
implicated in at least one ADR, count of OLUL medicine courses
implicated in at least one ADR.
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